Alnylam Pharmaceuticals, Inc. vs Meta Platforms Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $223.98 (market cap $29.60B), while Meta Platforms Inc trades at $578.96 (market cap $1.53T). The key difference: Meta Platforms Inc is far larger — about 51.7× Alnylam Pharmaceuticals, Inc.'s market cap, and Meta Platforms Inc pays a 0.35% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | META | |
|---|---|---|
Market Cap | $29.60B | $1.53T |
Sector | Health | Media |
52-Week High | $491.22 | $790.00 |
52-Week Low | $205.48 | $525.72 |
Enterprise Value | $27.56B | $1.55T |
Volume | — | 24,093,972 |
Dividend Yield | — | 0.35% |
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $222.54, up 2.56% today, amid a bearish technical signal with support at $218 and resistance at $223. The company reported strong revenue growth to $3.71B in 2025 and turned profitable with net income of $313.75M, though recent Q2 2026 earnings missed estimates. Analyst consensus remains bullish with a $370.07 price target, but multiple law firms are investigating potential securities fraud, creating near-term uncertainty.
The outlook is mixed: robust fundamentals and analyst support suggest long-term upside, but legal risks and recent earnings volatility pose significant headwinds. Investors face tension between strong profitability metrics and heightened sentiment risks from ongoing investigations.
META stock trades at $581.30, down 2.29% over 24 hours. The technical picture is neutral, with the price near key support at $580. Fundamentally, the company reported strong revenue of $200.97B for 2025 and a net income margin of 29.84%, though Q2 2026 EPS missed expectations. Recent news highlights the launch of the Muse Spark AI model and a significant legal ruling in Massachusetts.
The outlook is positive, supported by a strong analyst consensus (79% Buy) and a $761.95 price target. Key opportunities include AI monetization and revenue growth, while risks involve high capital expenditure, legal challenges, and competitive pressures in the social media and AI sectors.
Trailing returns across standard periods
Latest headlines on both assets
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →Meta Platforms Inc., doing business as Meta and previously known as Facebook Inc. It's a company that acts as a parent platform for Facebook, Messenger, Instagram, Whatsapp, Oculus and other subsidiaries. Among these platforms, Facebook is the number one social media platform in terms of the number of active users.
Read more on META →